Randox Laboratories Receive Queen's Award

This is the fifth time that Randox have won this award. Awards for Export Achievement were granted to the company in 1990, 1993, 1997, and the Queens Award for Enterprise in 2001. The Queens award is a coveted commercial prize and is a testimony to the hard work and dedication of Randox in the global diagnostics market.

Randox is a privately owned international clinical diagnostics company, exporting 95% of all products to over 130 countries with offices in 26 countries worldwide. Randox now manufactures 5% of the world's clinical chemistry products and ranks 23rd in the US$20 billion global clinical diagnostics market.

Randox reinvests 20% of annual revenue to improve diagnostic tests. Products cover a range of disease areas, including cancer, cardiovascular disease, diabetes, and a range of applications including drugs of abuse, thyroid, and fertility testing. Randox Laboratories has invested over UK£75 million to develop the world's first automated protein biochip array multi-analyte testing platform.

This reinforces Randox's mission statement to improve and revolutionize healthcare through continuously improving diagnostic systems and has lead to the introduction of many novel tests. One of the tests includes a novel diagnostic cardiovascular kit that significantly improves the early diagnosis of cardiac events.

The company develops, manufactures, and markets clinical diagnostic products worldwide. Core products include: biochip array technology; clinical chemistry analyzers and reagents; quality controls and EQA; environmental diagnostics; recombinant proteins, and antibodies. Randox production facilities are U.S. Food and Drug Administration- (FDA)-compliant, and the company currently claims to have more tests in development than any other diagnostic company in the world.


Related Links:
Randox Laboratories